Lappuse 1 no 39 rezultātiem
FIELD OF THE INVENTION
The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers, and specifically relates to 4'-O-glycosyl-etoposides as prodrugs
FIELD OF THE INVENTION
The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers, and specifically relates to 4'-O-glycosyl-etoposides as prodrugs
FIELD OF THE INVENTION
The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers, and specifically relates to 4'-O-glycosyl-etoposides as prodrugs
FIELD OF THE INVENTION
The present invention relates to a new synthetic process for the preparation of the anti-tumor agent etoposide.
BACKGROUND OF THE INVENTION
Etoposide (VP16-213), a semi-synthetic anti-tumor drug, is used effectively for the treatment of acute monocytic leukemia (Schilling's
CROSS-REFERENCES TO RELATED APPLICATIONS
This application is the U.S. National Stage of International Application No. PCT/EP2011/001960, filed Apr. 18, 2011, which designated the United States and has been published as International Publication No. WO 2011/128115 and which claims the priority of
FIELD OF THE INVENTION
The present invention pertains to the use of podophyllotoxin derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells (CSC). The invention discloses the surprisingly specific activity of the compounds in
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage Application of International Application Number PCT/EP2014/054785, filed Mar. 12, 2014; which claims priority to Great Britain Application No. 1304417.7, filed Mar. 12, 2013; both of which are incorporated herein by
The present invention relates to etoposide derivatives, to a process for preparing them and to their use as an anticancer medicinal product.
Etoposide a and some of its derivatives such as teniposide b ##STR2## are known to have antitumor activities which are useful in human clinical medicine. They
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application No. 61/133,478 filed Jun. 30, 2008.
FIELD OF THE INVENTION
The present application relates generally to a method of determining tumor cell
Throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
Histone acetylation is a reversible
PRIORITY CLAIM
This application claims the benefit of the filing date of Taiwan Patent Application No. 103114133, filed Apr. 18, 2014, entitled "INHALATION-TYPE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LUNG CANCER AND PREPARATION METHOD THEREOF," and the contents of which are hereby
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a novel method for the delivery of cytotoxic agents to tumor cells by the combined use of antibody-enzyme conjugates and prodrugs. More particularly, this invention relates to a method for the delivery of cytotoxic drugs to the site
FIELD OF THE INVENTION
The invention relates to compositions comprising combinations of anti-cancer drugs and methods of using the compositions for the the treatment of cancer.
BACKGROUND
5,6-dimethylxanthenone-4-acetic acid (DMXAA) is represented by the following formula:
##STR00001##
Phase I
FIELD OF THE INVENTION
The invention relates to compositions comprising combinations of anti-cancer drugs and methods of using the compositions for the treatment of cancer.
BACKGROUND
5,6-dimethylxanthenone-4-acetic acid (DMXAA) is represented by the following formula:
##STR00001##
Phase I clinical
This application is the U.S. National Phase of, and Applicants claim priority from, International Application Number PCT/CU2007/000010 filed 28 Feb. 2007 and Cuban Application bearing Serial No. CU 2006-0049 filed 28 Feb. 2006, which are incorporated herein by reference.
TECHNICAL FIELD
The present